Page 13 - Global Impression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia . Addex TherapeuticsJune 29, 2021 GMT Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease (PD-LID). Dyskinesia is believed to be caused by increased glutamatergic neurotransmission. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5, or mGlu5 to downregulate this neurotransmission through allosteric modulation.

United statesTim dyerMike sinclairMovement disordersJanssen pharmaceuticalsAddex therapeutics ltdJanssen pharmaceuticals incSwiss exchangeTherapeutics ltdUnified dyskinesia rating scaleGlobal impressionChief executive officerNew england journalAmerican depositary sharesHalsin partnersஒன்றுபட்டது மாநிலங்களில்